Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells.

Cell death & disease - 18 Jul 2018

Her Nam-Gu, Oh Jeong-Woo, Oh Yun Jeong, Han Suji, Cho Hee Jin, Lee Yeri, Ryu Gyu Ha, Nam Do-Hyun

Abstract excerpt

Testing new ways to identify untapped opportunities for glioblastoma therapies remains highly significant. Amplification and overexpression of MDM2 gene is frequent in glioblastoma and disrupting the MDM2-p53 interaction is a promising strategy to treat the cancer. RG7112 is the first-in class inhibitor and recently discovered AMG232 is the most potent MDM2 inhibitor known to date. Here, we compared the effects...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetates
Share to Apoptosis
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Nestin

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Share to Zinc Finger E-box-Binding Homeobox 1

Source

Open in PubMed Open full text

Identifiers

PMID: 30022047
DOI: 10.1038/s41419-018-0825-1
PMCID: PMC6052082

Genes

MDM2
ZEB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells.PMID 30022047Read ↗

The MDM2–p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem CellsSemantic proximity Read ↗

Glioblastoma cancer stem cell biology: Potential theranostic targetsSemantic proximity Read ↗

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read ↗

A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem CellsSemantic proximity Read ↗

A multistep in silico approach identifies potential glioblastoma drug candidates via inclusive molecular targeting of glioblastoma stem cellsSemantic proximity Read ↗

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsSemantic proximity Read ↗

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxiaSemantic proximity Read ↗

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxiaSemantic proximity Read ↗

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type GlioblastomasSemantic proximity Read ↗

The p53 Pathway in GlioblastomaSemantic proximity Read ↗

Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like CellsSemantic proximity Read ↗

Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.